• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

最小化中和抗体对腺相关病毒 8 载体在肝脏中高效基因表达的抑制作用。

Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors.

机构信息

Division of Cell and Molecular Medicine, Center for Molecular Medicine, Jichi Medical University, Tochigi-ken, Japan.

出版信息

Mol Ther. 2013 Feb;21(2):318-23. doi: 10.1038/mt.2012.258. Epub 2012 Dec 18.

DOI:10.1038/mt.2012.258
PMID:23247100
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3594013/
Abstract

Neutralizing antibodies (NAbs) against adeno-associated viruses (AAVs) are known to interfere with AAV vector-mediated gene transfer by intravascular delivery. Evading the inhibitory effects of antibodies against AAV vectors is necessary for efficient transfer of therapeutic genes clinically. For this purpose, we tested the efficacy of saline flushing in order to avoid contact of vectors with NAbs present in blood. Direct injection of the AAV8 vector carrying the factor IX (FIX) gene into the portal vein of macaques using saline flushing achieved transgene-derived FIX expression (4.7 ± 2.10-10.1 ± 5.45% of normal human FIX concentration) in the presence of NAbs. Expression was as efficient as that (5.43 ± 2.59-12.68 ± 4.83%) in macaques lacking NAbs. We next tested the efficacy of saline flushing using less invasive balloon catheter-guided injection. This approach also resulted in efficient expression of transgene-derived FIX (2.5 ± 1.06-9.0 ± 2.37%) in the presence of NAbs (14-56× dilutions). NAbs at this range of titers reduced the efficiency of transduction in the macaque liver by 100-fold when the same vector was injected into mesenteric veins without balloon catheters. Our results suggest that portal vein-directed vector delivery strategies with flushing to remove blood are efficacious for minimizing the inhibitory effect of anti-AAV antibodies.

摘要

中和抗体(NAbs)对腺相关病毒(AAV)的干扰作用,众所周知,会干扰 AAV 载体介导的血管内基因传递。为了在临床上有效地转移治疗基因,需要规避针对 AAV 载体的抗体的抑制作用。为此,我们测试了盐水冲洗以避免载体与血液中存在的 NAb 接触的效果。使用盐水冲洗,通过直接将携带因子 IX(FIX)基因的 AAV8 载体注入猕猴门静脉,可以在存在 NAb 的情况下实现转基因衍生的 FIX 表达(4.7±2.10-10.1±5.45%的正常人 FIX 浓度)。表达效率与缺乏 NAb 的猕猴相当(5.43±2.59-12.68±4.83%)。接下来,我们使用侵入性较小的球囊导管引导注射来测试盐水冲洗的效果。在存在 NAb(14-56×稀释度)的情况下,这种方法也能有效地表达转基因衍生的 FIX(2.5±1.06-9.0±2.37%)。当相同的载体在没有球囊导管的情况下注入肠系膜静脉时,该范围内的 NAb 滴度将转导效率降低了 100 倍。我们的研究结果表明,采用冲洗以清除血液的门静脉靶向载体传递策略对于最大限度地减少抗 AAV 抗体的抑制作用是有效的。

相似文献

1
Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors.最小化中和抗体对腺相关病毒 8 载体在肝脏中高效基因表达的抑制作用。
Mol Ther. 2013 Feb;21(2):318-23. doi: 10.1038/mt.2012.258. Epub 2012 Dec 18.
2
Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques.在恒河猴体内,肌肉注射腺相关病毒可克服预先存在的中和抗体。
Vaccine. 2016 Dec 7;34(50):6323-6329. doi: 10.1016/j.vaccine.2016.10.053. Epub 2016 Nov 3.
3
Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy.短暂免疫抑制对恒河猴腺相关病毒介导的肝靶向基因转移的影响及其对人类基因治疗的意义。
Blood. 2006 Nov 15;108(10):3321-8. doi: 10.1182/blood-2006-04-017913. Epub 2006 Jul 25.
4
In Utero Transfer of Adeno-Associated Viral Vectors Produces Long-Term Factor IX Levels in a Cynomolgus Macaque Model.腺相关病毒载体的子宫内转移在食蟹猴模型中产生长期的因子IX水平。
Mol Ther. 2017 Aug 2;25(8):1843-1853. doi: 10.1016/j.ymthe.2017.04.003. Epub 2017 Apr 24.
5
Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B.首例体内血管内给药的腺相关病毒基因治疗的长期随访:用于严重血友病 B 的 AAV2-hFIX16。
Mol Ther. 2020 Sep 2;28(9):2073-2082. doi: 10.1016/j.ymthe.2020.06.001. Epub 2020 Jun 10.
6
Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.利用替代型腺相关病毒血清型实现激活的因子 VII 的基因传递可改善携带 FVIII 抑制剂和腺相关病毒中和抗体的血友病小鼠的止血效果。
Hum Gene Ther. 2017 Aug;28(8):654-666. doi: 10.1089/hum.2017.016. Epub 2017 May 5.
7
The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques.天然 AAV 感染对食蟹猴肝脏靶向基因转移的多效性影响。
Mol Ther. 2010 Jan;18(1):126-34. doi: 10.1038/mt.2009.245. Epub 2009 Nov 3.
8
Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.利用功能获得性因子IX变体R338L提高B型血友病人类基因治疗的疗效和安全性:支持正在进行的腺相关病毒临床试验的临床前评估
Hum Gene Ther. 2015 Feb;26(2):69-81. doi: 10.1089/hum.2014.106. Epub 2015 Jan 21.
9
Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B.在用于乙型血友病的 AAV 基因转移的非人灵长类动物模型中对体液免疫的药理学调节。
Mol Ther. 2012 Jul;20(7):1410-6. doi: 10.1038/mt.2012.84. Epub 2012 May 8.
10
Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses.优化的腺相关病毒(AAV)-蛋白磷酸酶-5 辅助病毒,用于单链 AAV 载体高效转染肝脏:降低载体剂量时因子 IX 的治疗性表达。
Hum Gene Ther. 2010 Mar;21(3):271-83. doi: 10.1089/hum.2009.100.

引用本文的文献

1
Advances and Challenges in Adeno-Associated Virus Gene Therapy Applications of Localized Delivery Strategies.腺相关病毒基因治疗局部递送策略的进展与挑战
Curr Med Sci. 2025 Jul 15. doi: 10.1007/s11596-025-00084-6.
2
The curious case of AAV immunology.腺相关病毒免疫学的奇特案例。
Mol Ther. 2025 May 7;33(5):1946-1965. doi: 10.1016/j.ymthe.2025.03.037. Epub 2025 Mar 27.
3
Understanding AAV vector immunogenicity: from particle to patient.了解 AAV 载体的免疫原性:从粒子到患者。
Theranostics. 2024 Jan 20;14(3):1260-1288. doi: 10.7150/thno.89380. eCollection 2024.
4
Efficient gene transduction in pigs and macaques with the engineered AAV vector AAV.GT5 for hemophilia B gene therapy.使用工程化腺相关病毒载体AAV.GT5在猪和猕猴中进行高效基因转导用于B型血友病基因治疗。
Mol Ther Methods Clin Dev. 2023 Aug 22;30:502-514. doi: 10.1016/j.omtm.2023.08.016. eCollection 2023 Sep 14.
5
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer.腺相关病毒(AAV)载体的基因转移免疫原性。
BioDrugs. 2023 May;37(3):311-329. doi: 10.1007/s40259-023-00585-7. Epub 2023 Mar 2.
6
Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy.抗 AAV 结合和中和抗体:检测及对 rAAV 介导基因治疗的影响。
Mol Ther. 2023 Mar 1;31(3):616-630. doi: 10.1016/j.ymthe.2023.01.010. Epub 2023 Jan 11.
7
rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis.rAAV 免疫原性、毒性和持久性的 255 项临床试验的荟萃分析。
Front Immunol. 2022 Oct 27;13:1001263. doi: 10.3389/fimmu.2022.1001263. eCollection 2022.
8
The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs.日本血友病患者中针对腺相关病毒衣壳的中和抗体血清阳性率。
Mol Ther Methods Clin Dev. 2022 Oct 27;27:404-414. doi: 10.1016/j.omtm.2022.10.014. eCollection 2022 Dec 8.
9
Overcoming the Challenges Imposed by Humoral Immunity to AAV Vectors to Achieve Safe and Efficient Gene Transfer in Seropositive Patients.克服腺相关病毒载体的体液免疫挑战,实现血清阳性患者的安全高效基因转移。
Front Immunol. 2022 Apr 7;13:857276. doi: 10.3389/fimmu.2022.857276. eCollection 2022.
10
Adeno-Associated Viruses (AAV) and Host Immunity - A Race Between the Hare and the Hedgehog.腺相关病毒(AAV)和宿主免疫 - 野兔和刺猬之间的竞赛。
Front Immunol. 2021 Oct 29;12:753467. doi: 10.3389/fimmu.2021.753467. eCollection 2021.

本文引用的文献

1
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.腺相关病毒载体介导的乙型血友病基因转移。
N Engl J Med. 2011 Dec 22;365(25):2357-65. doi: 10.1056/NEJMoa1108046. Epub 2011 Dec 10.
2
Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity.通过衣壳工程增强 AAV 载体的临床潜力以逃避预先存在的免疫。
Front Microbiol. 2011 Oct 4;2:204. doi: 10.3389/fmicb.2011.00204. eCollection 2011.
3
AAV-mediated liver-directed gene therapy.腺相关病毒介导的肝脏靶向基因治疗。
Methods Mol Biol. 2011;807:141-57. doi: 10.1007/978-1-61779-370-7_6.
4
Adeno-associated virus antibody profiles in newborns, children, and adolescents.新生儿、儿童及青少年的腺相关病毒抗体谱
Clin Vaccine Immunol. 2011 Sep;18(9):1586-8. doi: 10.1128/CVI.05107-11. Epub 2011 Jul 20.
5
Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.前瞻性研究抗腺相关病毒中和抗体在血友病患儿中的作用。
Gene Ther. 2012 Mar;19(3):288-94. doi: 10.1038/gt.2011.90. Epub 2011 Jun 23.
6
Immune responses to AAV in clinical trials.临床试验中对 AAV 的免疫反应。
Curr Gene Ther. 2011 Aug;11(4):321-30. doi: 10.2174/156652311796150354.
7
A barrel of monkeys: scAAV8 gene therapy for hemophilia in nonhuman primates.一群猴子:非人类灵长类动物中用于血友病的scAAV8基因疗法。
Mol Ther. 2011 May;19(5):826-7. doi: 10.1038/mt.2011.73.
8
Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.经系统给予编码人凝血因子 IX 的自我互补型 AAV 载体(假型 5 型和 8 型衣壳蛋白)后,其长期安全性和疗效。
Mol Ther. 2011 May;19(5):876-85. doi: 10.1038/mt.2010.274. Epub 2011 Jan 18.
9
Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy.先天免疫和灵长类动物中的低表达突出了肝靶向 AAV8 介导的基因治疗的转化挑战。
Mol Ther. 2010 Nov;18(11):1983-94. doi: 10.1038/mt.2010.175. Epub 2010 Aug 24.
10
Mutant macaque factor IX T262A: a tool for hemophilia B gene therapy studies in macaques.突变猕猴因子 IX T262A:用于猕猴血友病 B 基因治疗研究的工具。
Thromb Res. 2010 Jun;125(6):533-7. doi: 10.1016/j.thromres.2010.01.049. Epub 2010 Feb 18.